Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 218 entries
Sorted by: Best Match Show Resources per page
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.

Breast cancer research : BCR

Brett JO, Spring LM, Bardia A, Wander SA.
PMID: 34392831
Breast Cancer Res. 2021 Aug 15;23(1):85. doi: 10.1186/s13058-021-01462-3.

In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase inhibition. How these mutations affect tumor sensitivity to established and novel therapies are active areas...

Cite
Brett JO, Spring LM, Bardia A, et al. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23(1):85doi: 10.1186/s13058-021-01462-3.
Brett, J. O., Spring, L. M., Bardia, A., & Wander, S. A. (2021). ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast cancer research : BCR, 23(1), 85. https://doi.org/10.1186/s13058-021-01462-3
Brett, Jamie O, et al. "ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer." Breast cancer research : BCR vol. 23,1 (2021): 85. doi: https://doi.org/10.1186/s13058-021-01462-3
Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021 Aug 15;23(1):85. doi: 10.1186/s13058-021-01462-3. PMID: 34392831; PMCID: PMC8365900.
Copy Download .nbib Format: NLM
Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.

Essays in biochemistry

Haines CN, Wardell SE, McDonnell DP.
PMID: 34328178
Essays Biochem. 2021 Dec 17;65(6):985-1001. doi: 10.1042/EBC20200174.

Nearly 80% of all breast cancers are estrogen receptor positive (ER+) and require the activity of this transcription factor for tumor growth and survival. Thus, endocrine therapies, which target the estrogen signaling axis, have and will continue to be...

Cite
Haines CN, Wardell SE, McDonnell DP. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer. Essays Biochem. 2021;65(6):985-1001doi: 10.1042/EBC20200174.
Haines, C. N., Wardell, S. E., & McDonnell, D. P. (2021). Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer. Essays in biochemistry, 65(6), 985-1001. https://doi.org/10.1042/EBC20200174
Haines, Corinne N, et al. "Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer." Essays in biochemistry vol. 65,6 (2021): 985-1001. doi: https://doi.org/10.1042/EBC20200174
Haines CN, Wardell SE, McDonnell DP. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer. Essays Biochem. 2021 Dec 17;65(6):985-1001. doi: 10.1042/EBC20200174. PMID: 34328178.
Copy Download .nbib Format: NLM
Selective estrogen receptor modulators against Gram-positive and Gram-negative bacteria: an experimental study.

Future microbiology

Garg A, Singh A, Kumar A.
PMID: 34406075
Future Microbiol. 2021 Sep;16:987-1001. doi: 10.2217/fmb-2020-0310. Epub 2021 Aug 18.

No abstract available.

Cite
Garg A, Singh A, Kumar A. Selective estrogen receptor modulators against Gram-positive and Gram-negative bacteria: an experimental study. Future Microbiol. 2021;16:987-1001doi: 10.2217/fmb-2020-0310.
Garg, A., Singh, A., & Kumar, A. (2021). Selective estrogen receptor modulators against Gram-positive and Gram-negative bacteria: an experimental study. Future microbiology, 16987-1001. https://doi.org/10.2217/fmb-2020-0310
Garg, Aakriti, et al. "Selective estrogen receptor modulators against Gram-positive and Gram-negative bacteria: an experimental study." Future microbiology vol. 16 (2021): 987-1001. doi: https://doi.org/10.2217/fmb-2020-0310
Garg A, Singh A, Kumar A. Selective estrogen receptor modulators against Gram-positive and Gram-negative bacteria: an experimental study. Future Microbiol. 2021 Sep;16:987-1001. doi: 10.2217/fmb-2020-0310. Epub 2021 Aug 18. PMID: 34406075.
Copy Download .nbib Format: NLM
Role of cholesterol metabolism in the anticancer pharmacology of selective estrogen receptor modulators.

Seminars in cancer biology

Gómez-Coronado D, Lasunción MA, Martínez-Botas J, Fernández-Suárez ME.
PMID: 32931953
Semin Cancer Biol. 2021 Aug;73:101-115. doi: 10.1016/j.semcancer.2020.08.015. Epub 2020 Sep 12.

Selective estrogen receptor modulators (SERMs) are a class of compounds that bind to estrogen receptors (ERs) and possess estrogen agonist or antagonist actions in different tissues. As such, they are widely used drugs. For instance, tamoxifen, the most prescribed...

Cite
Gómez-Coronado D, Lasunción MA, Martínez-Botas J, et al. Role of cholesterol metabolism in the anticancer pharmacology of selective estrogen receptor modulators. Semin Cancer Biol. 2020;73:101-115doi: 10.1016/j.semcancer.2020.08.015.
Gómez-Coronado, D., Lasunción, M. A., Martínez-Botas, J., & Fernández-Suárez, M. E. (2021). Role of cholesterol metabolism in the anticancer pharmacology of selective estrogen receptor modulators. Seminars in cancer biology, 73101-115. https://doi.org/10.1016/j.semcancer.2020.08.015
Gómez-Coronado, Diego, et al. "Role of cholesterol metabolism in the anticancer pharmacology of selective estrogen receptor modulators." Seminars in cancer biology vol. 73 (2021): 101-115. doi: https://doi.org/10.1016/j.semcancer.2020.08.015
Gómez-Coronado D, Lasunción MA, Martínez-Botas J, Fernández-Suárez ME. Role of cholesterol metabolism in the anticancer pharmacology of selective estrogen receptor modulators. Semin Cancer Biol. 2021 Aug;73:101-115. doi: 10.1016/j.semcancer.2020.08.015. Epub 2020 Sep 12. PMID: 32931953.
Copy Download .nbib Format: NLM
Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer.

Cell death & disease

Peng WX, Koirala P, Zhou H, Jiang J, Zhang Z, Yang L, Mo YY.
PMID: 34697301
Cell Death Dis. 2021 Oct 25;12(11):1000. doi: 10.1038/s41419-021-04288-1.

Selective estrogen receptor modulators (SERMs) such as tamoxifen have proven to be effective in the treatment of estrogen receptor (ER) positive breast cancer. However, a major obstacle for such endocrine therapy is estrogen independent growth, leading to resistance, and...

Cite
Peng WX, Koirala P, Zhou H, et al. Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer. Cell Death Dis. 2021;12(11):1000doi: 10.1038/s41419-021-04288-1.
Peng, W. X., Koirala, P., Zhou, H., Jiang, J., Zhang, Z., Yang, L., & Mo, Y. Y. (2021). Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer. Cell death & disease, 12(11), 1000. https://doi.org/10.1038/s41419-021-04288-1
Peng, Wan-Xin, et al. "Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer." Cell death & disease vol. 12,11 (2021): 1000. doi: https://doi.org/10.1038/s41419-021-04288-1
Peng WX, Koirala P, Zhou H, Jiang J, Zhang Z, Yang L, Mo YY. Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer. Cell Death Dis. 2021 Oct 25;12(11):1000. doi: 10.1038/s41419-021-04288-1. PMID: 34697301; PMCID: PMC8546148.
Copy Download .nbib Format: NLM
Endocrine prevention of breast cancer.

Molecular and cellular endocrinology

Jahan N, Jones C, Rahman RL.
PMID: 33882282
Mol Cell Endocrinol. 2021 Jun 15;530:111284. doi: 10.1016/j.mce.2021.111284. Epub 2021 Apr 18.

Breast cancer (BC) is the most common non-cutaneous malignancy among women worldwide and is a significant cause of morbidity, mortality, and national health care expenditure. Unfortunately, with few exceptions like alcohol consumption, obesity, and physical activity, most BC risk...

Cite
Jahan N, Jones C, Rahman RL. Endocrine prevention of breast cancer. Mol Cell Endocrinol. 2021;530:111284doi: 10.1016/j.mce.2021.111284.
Jahan, N., Jones, C., & Rahman, R. L. (2021). Endocrine prevention of breast cancer. Molecular and cellular endocrinology, 530111284. https://doi.org/10.1016/j.mce.2021.111284
Jahan, Nusrat, et al. "Endocrine prevention of breast cancer." Molecular and cellular endocrinology vol. 530 (2021): 111284. doi: https://doi.org/10.1016/j.mce.2021.111284
Jahan N, Jones C, Rahman RL. Endocrine prevention of breast cancer. Mol Cell Endocrinol. 2021 Jun 15;530:111284. doi: 10.1016/j.mce.2021.111284. Epub 2021 Apr 18. PMID: 33882282.
Copy Download .nbib Format: NLM
Selective Estrogen Receptor Modulators in COVID-19: A Possible Therapeutic Option?.

Frontiers in pharmacology

Calderone A, Menichetti F, Santini F, Colangelo L, Lucenteforte E, Calderone V.
PMID: 32765279
Front Pharmacol. 2020 Jul 15;11:1085. doi: 10.3389/fphar.2020.01085. eCollection 2020.

No abstract available.

Cite
Calderone A, Menichetti F, Santini F, et al. Selective Estrogen Receptor Modulators in COVID-19: A Possible Therapeutic Option?. Front Pharmacol. 2020;11:1085doi: 10.3389/fphar.2020.01085.
Calderone, A., Menichetti, F., Santini, F., Colangelo, L., Lucenteforte, E., & Calderone, V. (2020). Selective Estrogen Receptor Modulators in COVID-19: A Possible Therapeutic Option?. Frontiers in pharmacology, 111085. https://doi.org/10.3389/fphar.2020.01085
Calderone, Alba, et al. "Selective Estrogen Receptor Modulators in COVID-19: A Possible Therapeutic Option?." Frontiers in pharmacology vol. 11 (2020): 1085. doi: https://doi.org/10.3389/fphar.2020.01085
Calderone A, Menichetti F, Santini F, Colangelo L, Lucenteforte E, Calderone V. Selective Estrogen Receptor Modulators in COVID-19: A Possible Therapeutic Option?. Front Pharmacol. 2020 Jul 15;11:1085. doi: 10.3389/fphar.2020.01085. eCollection 2020. PMID: 32765279; PMCID: PMC7381128.
Copy Download .nbib Format: NLM
Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial.

JAMA oncology

Fan Y, Sun T, Shao Z, Zhang Q, Ouyang Q, Tong Z, Wang S, Luo Y, Teng Y, Wang X, Wang S, Liu Q, Feng J, Shen K, Song Y, Wang J, Ma F, Li Q, Zhang P, Xu B.
PMID: 34436536
JAMA Oncol. 2021 Oct 01;7(10):e213428. doi: 10.1001/jamaoncol.2021.3428. Epub 2021 Oct 21.

IMPORTANCE: The effectiveness of the mammalian target of rapamycin (mTOR) inhibitor everolimus in premenopausal women with hormone receptor (HR)-positive/ERBB2-negative advanced breast cancer who experienced disease progression while receiving selective estrogen receptor modulators (SERMs) is unknown.OBJECTIVE: To compare the effectiveness...

Cite
Fan Y, Sun T, Shao Z, et al. Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(10):e213428doi: 10.1001/jamaoncol.2021.3428.
Fan, Y., Sun, T., Shao, Z., Zhang, Q., Ouyang, Q., Tong, Z., Wang, S., Luo, Y., Teng, Y., Wang, X., Wang, S., Liu, Q., Feng, J., Shen, K., Song, Y., Wang, J., Ma, F., Li, Q., Zhang, P., & Xu, B. (2021). Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial. JAMA oncology, 7(10), e213428. https://doi.org/10.1001/jamaoncol.2021.3428
Fan, Ying, et al. "Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial." JAMA oncology vol. 7,10 (2021): e213428. doi: https://doi.org/10.1001/jamaoncol.2021.3428
Fan Y, Sun T, Shao Z, Zhang Q, Ouyang Q, Tong Z, Wang S, Luo Y, Teng Y, Wang X, Wang S, Liu Q, Feng J, Shen K, Song Y, Wang J, Ma F, Li Q, Zhang P, Xu B. Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Oct 01;7(10):e213428. doi: 10.1001/jamaoncol.2021.3428. Epub 2021 Oct 21. PMID: 34436536; PMCID: PMC8391779.
Copy Download .nbib Format: NLM
Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?.

International journal of endocrinology

Giagulli VA, Silvestrini A, Bruno C, Triggiani V, Mordente A, Mancini A.
PMID: 32411230
Int J Endocrinol. 2020 Jan 21;2020:9649838. doi: 10.1155/2020/9649838. eCollection 2020.

Hypogonadotropic hypogonadism (HH) can be sustained by organic or functional alterations of the hypothalamic-pituitary-testicular axis. Functional HH is related to systemic alterations, such as obesity or chronic inflammatory diseases, but could contribute to a negative course of the illness....

Cite
Giagulli VA, Silvestrini A, Bruno C, et al. Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?. Int J Endocrinol. 2020;2020:9649838doi: 10.1155/2020/9649838.
Giagulli, V. A., Silvestrini, A., Bruno, C., Triggiani, V., Mordente, A., & Mancini, A. (2020). Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?. International journal of endocrinology, 20209649838. https://doi.org/10.1155/2020/9649838
Giagulli, Vito A, et al. "Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?." International journal of endocrinology vol. 2020 (2020): 9649838. doi: https://doi.org/10.1155/2020/9649838
Giagulli VA, Silvestrini A, Bruno C, Triggiani V, Mordente A, Mancini A. Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?. Int J Endocrinol. 2020 Jan 21;2020:9649838. doi: 10.1155/2020/9649838. eCollection 2020. PMID: 32411230; PMCID: PMC7201459.
Copy Download .nbib Format: NLM
The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women.

Journal of bone oncology

Rouach V, Goldshtein I, Buch A, Catane R, Chodick G, Stern N, Shalev V, Cohen D.
PMID: 31334001
J Bone Oncol. 2018 Nov 06;16:100202. doi: 10.1016/j.jbo.2018.10.001. eCollection 2019 Jun.

BACKGROUND: Several observational studies have suggested a protective effect of oral bisphosphonates (BP) on the risk of breast cancer, but no such association has been seen in randomized control trials. The role of oral BP in breast cancer prevention...

Cite
Rouach V, Goldshtein I, Buch A, et al. The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women. J Bone Oncol. 2018;16:100202doi: 10.1016/j.jbo.2018.10.001.
Rouach, V., Goldshtein, I., Buch, A., Catane, R., Chodick, G., Stern, N., Shalev, V., & Cohen, D. (2019). The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women. Journal of bone oncology, 16100202. https://doi.org/10.1016/j.jbo.2018.10.001
Rouach, Vanessa, et al. "The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women." Journal of bone oncology vol. 16 (2019): 100202. doi: https://doi.org/10.1016/j.jbo.2018.10.001
Rouach V, Goldshtein I, Buch A, Catane R, Chodick G, Stern N, Shalev V, Cohen D. The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women. J Bone Oncol. 2018 Nov 06;16:100202. doi: 10.1016/j.jbo.2018.10.001. eCollection 2019 Jun. PMID: 31334001; PMCID: PMC6616345.
Copy Download .nbib Format: NLM
Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity.

Bioorganic chemistry

Ragab MA, Elagawany M, Daabees H, Ahmed AF, Awad EM, Billon C, Elgendy B, Abouzid KAM, Kassab SE.
PMID: 34923243
Bioorg Chem. 2021 Dec 13;119:105554. doi: 10.1016/j.bioorg.2021.105554. Epub 2021 Dec 13.

Nuclear Estrogen receptors (ER) are cytoplasmic proteins; translocated to the nucleus to induce transcriptional signals after getting bound to the estrogen hormone. ER activation implicated in cancer cell proliferation of female reproductive organs. Thus, the discovery of ER antagonists...

Cite
Ragab MA, Elagawany M, Daabees H, et al. Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity. Bioorg Chem. 2021;119:105554doi: 10.1016/j.bioorg.2021.105554.
Ragab, M. A., Elagawany, M., Daabees, H., Ahmed, A. F., Awad, E. M., Billon, C., Elgendy, B., Abouzid, K. A. M., & Kassab, S. E. (2021). Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity. Bioorganic chemistry, 119105554. https://doi.org/10.1016/j.bioorg.2021.105554
Ragab, Mahmoud A, et al. "Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity." Bioorganic chemistry vol. 119 (2021): 105554. doi: https://doi.org/10.1016/j.bioorg.2021.105554
Ragab MA, Elagawany M, Daabees H, Ahmed AF, Awad EM, Billon C, Elgendy B, Abouzid KAM, Kassab SE. Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity. Bioorg Chem. 2021 Dec 13;119:105554. doi: 10.1016/j.bioorg.2021.105554. Epub 2021 Dec 13. PMID: 34923243.
Copy Download .nbib Format: NLM
Anabolic steroid misuse and male infertility: management and strategies to improve patient awareness.

Expert review of endocrinology & metabolism

Whitaker DL, Geyer-Kim G, Kim ED.
PMID: 33973822
Expert Rev Endocrinol Metab. 2021 May;16(3):109-122. doi: 10.1080/17446651.2021.1921574. Epub 2021 May 11.

No abstract available.

Cite
Whitaker DL, Geyer-Kim G, Kim ED. Anabolic steroid misuse and male infertility: management and strategies to improve patient awareness. Expert Rev Endocrinol Metab. 2021;16(3):109-122doi: 10.1080/17446651.2021.1921574.
Whitaker, D. L., Geyer-Kim, G., & Kim, E. D. (2021). Anabolic steroid misuse and male infertility: management and strategies to improve patient awareness. Expert review of endocrinology & metabolism, 16(3), 109-122. https://doi.org/10.1080/17446651.2021.1921574
Whitaker, Dustin L, et al. "Anabolic steroid misuse and male infertility: management and strategies to improve patient awareness." Expert review of endocrinology & metabolism vol. 16,3 (2021): 109-122. doi: https://doi.org/10.1080/17446651.2021.1921574
Whitaker DL, Geyer-Kim G, Kim ED. Anabolic steroid misuse and male infertility: management and strategies to improve patient awareness. Expert Rev Endocrinol Metab. 2021 May;16(3):109-122. doi: 10.1080/17446651.2021.1921574. Epub 2021 May 11. PMID: 33973822.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 218 entries